StockData
NGENNasdaqPharmaceutical PreparationsFiscal year ends December 31

NERVGEN PHARMA CORP.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026
$1.54−0.05 (-3.14%)

Close on Oct 19, 2026

SEC filings

15 of Nervgen Pharma's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report6-KSep 25, 2026Sep 25, 2026SEC EDGAR
Current report6-KSep 24, 2026Sep 24, 2026SEC EDGAR
Current report6-KAug 13, 2026Aug 13, 2026SEC EDGAR
Current report6-KJul 2, 2026Jul 2, 2026SEC EDGAR
Current report6-KJun 1, 2026Jun 1, 2026SEC EDGAR
Current report6-KMay 26, 2026May 26, 2026SEC EDGAR
Current report6-KMay 22, 2026May 22, 2026SEC EDGAR
Current report6-KMay 18, 2026May 18, 2026SEC EDGAR
Current report6-KMay 15, 2026May 15, 2026SEC EDGAR
Current report6-KApr 27, 2026Apr 27, 2026SEC EDGAR
Annual report40-FDec 31, 2025Mar 31, 2026SEC EDGAR
Current report6-KMar 13, 2026Mar 13, 2026SEC EDGAR
Current report6-KFeb 13, 2026Feb 13, 2026SEC EDGAR
Current report6-KFeb 10, 2026Feb 10, 2026SEC EDGAR
Current report6-KJan 8, 2026Jan 8, 2026SEC EDGAR